Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

Published:2018-09 Issue:9 Volume:13 Page:1312-1323
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Schrock Alexa B.,Zhu Viola W.,Hsieh Wen-Son,Madison Russell,Creelan Benjamin,Silberberg Jeffrey,Costin Dan,Bharne Anjali,Bonta Ioana,Bosemani Thangavijayan,Nikolinakos Petros,Ross Jeffrey S.,Miller Vincent A.,Ali Siraj M.,Klempner Samuel J.,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference41 articles.

1. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M;Thress;Nat Med,2015

2. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib;Ou;Lung Cancer,2017

3. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer;Gainor;Cancer Disc,2016

4. Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping;Schrock;J Thorac Oncol,2017

5. Circulating tumor DNA identifies EGFR coamplification as a mechanism of resistance to crizotinib in a patient with advanced MET-amplified lung adenocarcinoma;Dagogo-Jack;J Thorac Oncol,2017

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer;Frontiers in Pharmacology;2024-07-29

2. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02

3. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;Nature Communications;2024-06-14

4. Analysis of Clinical Features and Treatment Strategies in Advanced Lung Adenocarcinoma Patients With Acquired ALK Fusion After Resistance of EGFR-TKIs;2024-05-31

5. NTRK3-Rearranged Prostatic Acinar Adenocarcinoma: Report of a Patient and Review of the Literature;International Journal of Surgical Pathology;2024-05-21